Pam McKay, Haematologist Specialising in Lymphoma at Beatson Cancer Centre, shared Toby Eyre’s, CLL specialist at the Oxford University Hospitals, post on X, adding:
“Important international practice changing study – the end of HD MTX for CNS prophylaxis?”
Quoting Toby Eyre’s post:
“High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis | Journal of Clinical Oncology”
Title: High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Authors: Matthew R. Wilson, Katharine L. Lewis, Amy A. Kirkwood, Kate Cwynarski, Chan Y. Cheah, Tarec C. El-Galaly, Diego Villa, Kerry J. Savage, Paola Ghione, Sabela Bobillo, Karin E. Smedby, Sara Harrysson, Marek Trneny, Magdalena Klanova, Robert Puckrin, Christopher P. Fox, Mark Bishton, Gita Thanarajasingam, Nicole Wong Doo, Greg Hapgood, Carole Soussain, Sylvain Choquet, Michael Dickinson, Dipti Talaulikar, Sanjay de Mel, Gavin Preston, Matthew Ahearne, Eliza A. Hawkes, Elisabeth Schorb, Aline Clavert, Matthew Ku, Anna Guidetti, Mayur Narkhede, Teresa Calimeri, Eric Durot, Jeffrey Smith, Loïc Renaud, Pamela McKay, Toby A. Eyre
Other articles featuring Pam McKay and Toby Eyre on OncoDaily.